--- canonical_name: Fadogia agrestis alternate_names: Vangueria agrestis, Bakin Gagai, Black Aphrodisiac canonical_topic: Fadogia agrestis to Improve Testosterone short_topic_lc: fadogia_agrestis_testosterone creation_date: 2026-0723-0128 creator_ai_fullname: Opus 4.8 --- # Fadogia agrestis to Improve Testosterone
Evidence Review created on 07/23/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Vangueria agrestis, Bakin Gagai, Black Aphrodisiac ## Motivation *Fadogia agrestis* (also called *Vangueria agrestis*) is a flowering shrub from West Africa whose stem has long been used in traditional medicine. In recent years it has become a popular dietary supplement marketed to men who want to raise their testosterone and improve sexual function. Interest centers on the idea that the plant may prompt the body's own hormone signals to tell the testes to make more testosterone, rather than supplying a hormone directly. Much of the attention traces back to a handful of animal experiments in which rodents given the stem extract showed large jumps in testosterone and stronger sexual behavior, alongside public discussion by well-known health commentators. At the same time, those same animal studies hinted that higher amounts or longer use might harm the testes, liver, and kidneys. No human study has yet tested whether the supplement works or is safe. This review gathers what is currently known about *Fadogia agrestis* as a way to support testosterone. It examines the proposed biology, the animal evidence for benefits, the safety signals, the dosing and cycling ideas used in practice, and how the herb is sourced and monitored, so that where solid evidence ends and speculation begins is clear. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level, directly relevant expert and academic sources that discuss *Fadogia agrestis* and its use for testosterone support in substantial depth. * [The Science of How to Optimize Testosterone & Estrogen](https://www.hubermanlab.com/episode/the-science-of-how-to-optimize-testosterone-and-estrogen) - Andrew Huberman A detailed podcast episode in which the neuroscientist reviews behavioral and supplement-based approaches to raising testosterone, including his rationale for using *Fadogia agrestis* and Tongkat Ali, typical dosing, cycling, and the emphasis on bloodwork given the thin human safety data. * [Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats](https://pubmed.ncbi.nlm.nih.gov/16281088/) - Yakubu et al., 2005 The foundational study behind the herb's reputation, reporting dose-dependent increases in serum testosterone and sexual behavior in male rats; it is the single most-cited source for the testosterone claim and the anchor for essentially all downstream discussion. * [Quantification of Phenolic Compounds from Fadogia agrestis and Dietary Supplements using UHPLC-PDA-MS](https://pubmed.ncbi.nlm.nih.gov/30170324/) - Avula et al., 2019 An analytical study that measured marker phenolic compounds in raw *Fadogia agrestis* and in commercial supplements, offering a rare, evidence-based look at botanical identity and the variability of finished products on the market. *Note: Only three sources are listed because in-depth, directly relevant coverage of Fadogia agrestis is genuinely scarce — no human clinical literature exists, and among the priority experts only Andrew Huberman has produced dedicated content. Web and direct on-site searches found no dedicated Fadogia agrestis coverage from Rhonda Patrick, Peter Attia, Chris Kresser, or Life Extension. The list has not been padded with marginally relevant material.* ## Grokipedia [Vangueria agrestis](https://grokipedia.com/page/vangueria_agrestis) The dedicated Grokipedia page for the species (the accepted botanical name for *Fadogia agrestis*), covering its botany, distribution, traditional uses, and its modern role as a testosterone-support supplement. ## Examine [Fadogia agrestis](https://examine.com/supplements/fadogia-agrestis/) Examine's evidence-based supplement page summarizing the (rodent-only) research on *Fadogia agrestis* for testosterone and libido, its main drawbacks, and the cytotoxicity concerns, with an explicit note that no human studies have been conducted. ## ConsumerLab No dedicated ConsumerLab article, review, or test report exists for *Fadogia agrestis* as of 23 July 2026. ## Systematic Reviews No systematic reviews or meta-analyses for *Fadogia agrestis* were found on PubMed as of 23 July 2026. ## Mechanism of Action The proposed mechanism for *Fadogia agrestis* works through the body's central hormone loop, the hypothalamic-pituitary-gonadal axis (HPG axis, the feedback chain linking the brain to the testes). In this model, the extract raises the pituitary output of luteinizing hormone (LH, the messenger hormone that signals the testes to make testosterone). LH binds receptors on the testicular Leydig cells, raising cyclic adenosine monophosphate (cAMP, an internal signaling molecule) and driving the steroidogenic enzymes — including the steroidogenic acute regulatory protein (StAR) and the hydroxysteroid dehydrogenases (3β-HSD and 17β-HSD, enzymes that convert cholesterol step by step into testosterone). Because the effect is proposed to act upstream at the testes rather than by supplying a hormone, it is often framed as "stimulating" natural production. The animal data complicate this tidy picture, and competing explanations exist. In rat work by Yakubu and colleagues, testosterone rose sharply, but so did testicular weight and, at higher doses, markers of tissue damage — suggesting the same signaling that boosts output may, when overdriven, injure the Leydig and germ cells. An alternative reading is that the measured testosterone rise reflects a direct action on testicular tissue or altered enzyme activity rather than a clean LH-mediated signal, since the herb's alkaloid and saponin content can affect multiple pathways at once. A pro-sexual effect independent of testosterone — for example, through nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) in erectile tissue — has also been proposed and is supported by later rat studies of erectile function. As a pharmacological agent, *Fadogia agrestis* is poorly characterized. It is a multi-compound botanical extract rather than a single molecule; the specific constituent responsible for any hormonal effect has not been identified. There are no human data on half-life, receptor selectivity, or tissue distribution, and its metabolism is presumed to be hepatic (through cytochrome P450 (CYP) enzymes, the liver's main drug-processing system) but has not been formally studied. This absence of basic pharmacology is itself a key limitation of the evidence base. ## Historical Context & Evolution *Fadogia agrestis* has a documented history in the traditional medicine of West Africa, particularly Nigeria, where the Hausa name "Bakin Gagai" is used. The stem was employed as an aphrodisiac and to treat erectile difficulty, as well as for fever and as an antimalarial remedy — uses recorded in ethnobotanical surveys of the region. Its move from regional folk remedy toward global supplement began with laboratory pharmacology rather than clinical need. The pivotal event was a 2005 rat study (Yakubu and colleagues) that set out to test the traditional aphrodisiac claim and found that an aqueous stem extract raised serum testosterone in a dose-dependent way while increasing several measures of sexual behavior. Follow-up work from the same group examined testicular function and, separately, cellular toxicity in the liver and kidney, giving an early and unusually balanced picture: a signal of benefit accompanied by a signal of harm. The herb reached a broad audience roughly fifteen years later, when longevity- and performance-focused podcasters and clinicians began discussing it as a "natural" testosterone lever, frequently paired with Tongkat Ali (*Eurycoma longifolia*). That popular attention, not new human evidence, drove the surge in commercial products. The scientific standing of the original findings has not fundamentally changed: the rat data remain real and reproducible within the rodent model, but they have never been extended into humans. Rather than being overturned, the early work has simply not progressed — the open questions of whether the effect translates to people, and at what safety cost, are the same ones raised by the first studies. ## Expected Benefits The benefits below are drawn from the available preclinical literature and expert commentary. A dedicated search of PubMed, clinical references, and expert sources was performed to confirm that the benefit profile is complete. A defining feature of this intervention is that every proposed benefit rests on animal data or extrapolation; no randomized controlled trial (RCT, a study that randomly assigns participants to treatment or control) in humans exists. ### Low 🟩 #### Increased Testosterone Production The signature claim is that *Fadogia agrestis* raises circulating testosterone by stimulating the testes rather than supplying the hormone. The evidence basis is a small set of rodent studies, chiefly Yakubu et al., 2005, in which male rats given an aqueous stem extract showed clear, dose-dependent rises in serum testosterone. The grade is held to Low because, although the animal signal is direct and reproducible, there is no human confirmation, and rodent endocrine responses frequently fail to translate to people. **Magnitude:** In male rats, five days of stem extract raised serum testosterone roughly 2-fold at 18 mg/kg and up to about 6-fold at 100 mg/kg; no human data exist to quantify any effect. #### Enhanced Libido and Sexual Behavior Beyond hormone levels, the traditional use is as an aphrodisiac, and the rodent data support a pro-sexual effect. In Yakubu et al., 2005, treated rats showed increased mounting behavior and shorter latency to initiate sexual activity, changes that paralleled the testosterone rise but may also involve direct effects on erectile tissue. This remains Low evidence: the behavior is measured in rats, and human sexual-function outcomes have not been tested. **Magnitude:** In rats, the extract increased mount and intromission frequency and reduced mount latency in a dose-dependent manner versus untreated controls; comparable human figures are not available. #### Pro-Erectile / Erectile Function Support A later rat model suggests the herb may support erectile physiology specifically. In Ogunro & Yakubu, 2023, stem extract restored several biochemical markers of erectile function toward normal in the testicular and penile tissue of rats whose sexual function had been impaired by the antidepressant paroxetine. The proposed mechanism involves the nitric-oxide pathway in erectile tissue in addition to any androgen effect. The grade is Low because the work is animal-only and uses a drug-induced dysfunction model rather than healthy or aging humans. **Magnitude:** In paroxetine-treated rats, extract dosing moved erectile-function biomarkers back toward untreated-control values; no human effect size is established. ### Speculative 🟨 #### Increased Muscle Mass and Strength Because higher testosterone generally supports muscle protein synthesis, users often expect gains in lean mass and strength. No study — in animals or humans — has measured body composition or performance outcomes with *Fadogia agrestis*. This benefit is therefore purely an extrapolation from the presumed hormone effect and from anecdotal user reports, with no controlled data of any kind. #### Improved Mood, Energy, and Sense of Well-Being Some users and commentators describe better drive, mood, and energy, effects that would be plausible if testosterone rises meaningfully. The basis here is mechanistic and anecdotal only, including self-reported experiences shared publicly by health commentators; no controlled study has assessed mood, fatigue, or well-being endpoints for this herb. ## Benefit-Modifying Factors * **Baseline testosterone status:** Any real benefit is most plausible in men with low-normal or declining testosterone and intact testicular capacity. In primary testicular failure, an upstream, LH-driven mechanism would be expected to produce little, since the tissue cannot respond regardless of signal. * **Genetic variation in hormone response:** Androgen receptor sensitivity varies between individuals (for example, with the length of the androgen receptor CAG repeat, a stretch of DNA that tunes how strongly cells respond to testosterone), so the same hormone change could produce different subjective effects. Variation in CYP-family liver enzymes (which process the extract) may also alter internal exposure. * **Sex-based differences:** The entire benefit dataset comes from male rats. In women, any androgen-raising effect is far more likely to present as unwanted virilizing effects than as a desired benefit, so the risk-benefit balance is fundamentally different and untested. * **Age:** The target use case is typically men at the older end of the adult range with age-related testosterone decline, who in principle have the most to gain; however, older adults also clear compounds more slowly and are more vulnerable to the herb's organ-toxicity signals. * **Pre-existing health conditions:** Metabolic health, obesity, and conditions that suppress the HPG axis can blunt or distort any response, while liver or kidney impairment shifts the balance decisively toward risk over benefit. ## Potential Risks & Side Effects A dedicated search of drug-reference and toxicology sources and the primary literature was performed to characterize the safety profile. The central caveat mirrors the benefits: nearly all safety data come from rodents, and no human adverse-event record exists. Notably, the same research program that produced the benefit signal also produced the main safety signals. ### Low 🟥 #### Testicular Toxicity and Impaired Testicular Function The most specific concern is that the herb can damage the very organ it is meant to stimulate. In rat work by Yakubu and colleagues on testicular function indices, higher doses and longer dosing were associated with distortion of testicular architecture and adverse changes in testicular enzymes and function, even as testosterone rose at lower or shorter exposures. The proposed mechanism is overdriven signaling and direct cellular toxicity to Leydig and germ cells. This is graded Low because the evidence, though direct, is animal-only and no human threshold is defined. **Magnitude:** In rats, higher doses (around 100 mg/kg) and dosing beyond several days were linked to testicular tissue damage and impaired function; no equivalent human dose-toxicity threshold has been established. #### Hepatotoxicity and Nephrotoxicity *Fadogia agrestis* has shown a signal of liver and kidney injury in animals. In Yakubu et al., 2009, an aqueous stem extract produced dose-dependent evidence of liver and kidney cell-membrane damage — a leakage of cellular enzymes (alkaline phosphatase, lactate dehydrogenase, and gamma-glutamyl transferase) from the tissues into the blood, alongside a rise in malondialdehyde, a marker of oxidative membrane damage. This is the same kind of hepatocyte and nephron injury that clinical monitoring tracks with the aminotransferases ALT (alanine aminotransferase) and AST (aspartate aminotransferase), which rise when liver cells are injured. The mechanism appears to be direct cellular toxicity. It is graded Low: consistent in rodents, unquantified in humans. **Magnitude:** In rats dosed for up to 28 days, liver and kidney injury markers rose in a dose-dependent fashion across roughly 18–100 mg/kg; no human data exist to define a comparable range. ### Speculative 🟨 #### Erythrocytosis (Elevated Hematocrit) Agents that raise testosterone can also raise red-blood-cell production, increasing hematocrit (Hct, the share of blood volume made up of red cells) and, at the extreme, thickening the blood. No study has measured blood counts with *Fadogia agrestis*; this risk is inferred entirely from the known behavior of androgens and is therefore speculative. #### Estrogen Elevation and Gynecomastia If testosterone rises, some is converted to estrogen, which could in principle produce elevated estradiol and, rarely, breast tissue growth (gynecomastia) in men. This concern is mechanistic and echoed in anecdotal user reports and commentary, but no controlled data on estrogen effects of this herb exist. #### Prostate and Cardiovascular Concerns from Elevated Androgens Sustained increases in androgens are sometimes raised as theoretical concerns for prostate tissue and cardiovascular risk. For *Fadogia agrestis* specifically there is no evidence in either direction; the concern is a class-level extrapolation applied cautiously in the absence of any human safety follow-up. ## Risk-Modifying Factors * **Baseline liver and kidney function:** Because the clearest animal harms are hepatic and renal, pre-existing liver or kidney impairment is the single most important risk modifier, plausibly amplifying toxicity and reducing clearance. * **Genetic variation in metabolism:** Individual differences in CYP-family and conjugating (for example, UGT, the glucuronidation enzymes that help the liver excrete compounds) enzyme activity may raise internal exposure in slow metabolizers, potentially increasing organ stress. * **Sex-based differences:** Women face qualitatively different risks, including virilizing effects from androgen elevation and unknown effects in pregnancy or breastfeeding; none of this has been studied. * **Age:** Older adults, often the intended users, tend to have reduced hepatic and renal reserve and slower drug clearance, which can heighten susceptibility to the toxicity signals seen in animals. * **Pre-existing health conditions:** Hormone-sensitive conditions (such as prostate cancer), polycythemia (already-high red cell counts), and significant liver or kidney disease each shift the balance toward harm and are the situations in which caution is greatest. ## Key Interactions & Contraindications * **Prescription drug interactions:** Testosterone replacement therapy (TRT, prescribed testosterone) and anabolic steroids may have additive androgenic effects — caution, with risk of excess androgen load and elevated hematocrit. Other hepatotoxic drugs (for example, methotrexate, isoniazid, high-dose acetaminophen when prescribed) may compound the liver-injury signal — caution, additive hepatotoxicity. Anticoagulants such as warfarin warrant caution given possible additive effects on bleeding risk and shared liver metabolism — monitor. * **Over-the-counter medication interactions:** Acetaminophen (paracetamol) may add to hepatic stress — caution, additive liver strain, especially with alcohol. Non-steroidal anti-inflammatory drugs (NSAIDs, common pain relievers such as ibuprofen) may add to renal stress — caution given the animal kidney-toxicity signal. * **Supplement interactions:** Other pro-androgen or pro-libido botanicals — Tongkat Ali (*Eurycoma longifolia*), *Tribulus terrestris*, ashwagandha (*Withania somnifera*), boron, and DHEA (dehydroepiandrosterone, a hormone precursor sold as a supplement) — may have additive hormonal effects; monitor, as combined androgenic load is the practical concern. Hepatotoxic supplements (high-dose green tea extract, kava) may add to liver risk — caution. * **Additive-effect supplements:** Supplements that independently raise testosterone or luteinizing hormone — most notably Tongkat Ali, with which *Fadogia agrestis* is very commonly stacked — should be treated as additive to, not separate from, the herb's own effect when judging total androgen exposure and monitoring needs. * **Other intervention interactions:** Because effects on estrogen are plausible, concurrent use of aromatase inhibitors (anastrozole) or 5-alpha-reductase inhibitors (finasteride) could interact with any hormonal shift; this is theoretical and unstudied. * **Populations who should avoid it:** Men with hormone-sensitive cancers (for example, known or suspected prostate cancer) — absolute contraindication given androgen stimulation. People with significant liver disease (for example, Child-Pugh Class B or C) or chronic kidney disease (for example, eGFR (estimated glomerular filtration rate, a measure of kidney function) below 60) — avoid, given the organ-toxicity signals. Men actively trying to conceive — avoid, given testicular-toxicity findings. Women who are pregnant or breastfeeding, and anyone under 18 — avoid, as effects are untested and androgenic. Individuals with polycythemia (hematocrit above roughly 52%) — avoid, given the potential to further raise red cell counts. ## Risk Mitigation Strategies * **Conservative dosing:** Keeping to modest amounts (commonly 300–600 mg/day of stem extract rather than higher "mega-dose" regimens) directly limits the dose-dependent testicular, liver, and kidney toxicity seen in animals, where harm scaled with dose. * **Cycling rather than continuous use:** Using the herb in defined blocks (for example, 8 weeks on followed by several weeks off, or shorter 3-weeks-on / 1-week-off cycles) is intended to reduce cumulative organ exposure and to guard against the possibility of testicular strain or receptor desensitization with uninterrupted use. * **Baseline and periodic organ-function testing:** Checking liver enzymes (ALT, AST) and kidney markers (creatinine, eGFR) before starting and every 8–12 weeks addresses the hepatotoxicity and nephrotoxicity signals by catching injury early, while values are still reversible. * **Hormone and blood-count monitoring:** Measuring total and free testosterone, estradiol, and hematocrit before and during use lets a user confirm the intended effect and detect the speculative risks of excess estrogen conversion or rising red cell counts before they become clinically meaningful. * **Avoiding additive hepatic and androgenic loads:** Not combining the herb with alcohol, other hepatotoxic agents, or multiple stacked testosterone-boosting products at once reduces the compounded liver strain and total androgen exposure that drive most of the plausible harms. * **Using third-party-tested product:** Choosing a supplement verified by an independent laboratory for identity and contaminants mitigates the separate risk that a mislabeled or adulterated product delivers an unknown dose or unwanted compounds. ## Therapeutic Protocol * **Standard dose:** The most widely used regimen, popularized in the longevity and performance community by Andrew Huberman, is approximately 300–600 mg/day of *Fadogia agrestis* stem extract. There is no clinically validated dose; this range reflects practitioner and user convention, not trial-derived evidence. * **Cycling structure:** Practitioners generally treat it as an intermittent, not lifelong, agent — commonly 8–12 weeks of use followed by a break of several weeks, precisely because of the animal toxicity signals. Some users prefer shorter 3-weeks-on / 1-week-off cycles. * **Best time of day:** Morning dosing is typically suggested to align with the body's natural daily testosterone peak, though no timing study exists for this herb. * **Half-life and dosing frequency:** The human half-life of *Fadogia agrestis* is unknown, as no pharmacokinetic study has been performed; in the absence of data, it is most often taken once daily, though some users split the dose morning and midday. * **Genetic considerations:** Pharmacogenetically relevant variation (for example, in CYP-family metabolizing enzymes or androgen receptor CAG-repeat length) may in theory influence both exposure and subjective response, but no genotype-guided dosing is established. * **Sex-based differences:** Protocols are derived entirely from male use and male rat data; there is no basis for a dosing regimen in women, and androgenic effects make routine use in women inadvisable. * **Age-related considerations:** Older users, who are the most common target group, may warrant the lower end of the dose range and closer monitoring given reduced organ reserve and slower clearance. * **Baseline biomarker levels:** Response is most plausible in those with low-normal baseline testosterone; men already in a healthy range have less to gain and the same exposure to risk. * **Pre-existing conditions:** The presence of liver, kidney, prostate, or fertility concerns should, in practice, move the decision away from use entirely rather than toward a modified dose. * **Common stack:** In practice it is frequently combined with Tongkat Ali (*Eurycoma longifolia*); when stacked, the combined androgenic effect and monitoring burden should be considered together rather than for each herb in isolation. ## Discontinuation & Cycling * **Intended duration:** *Fadogia agrestis* is best understood as a short-term, cycled agent rather than a lifelong supplement; the toxicity signals in animals are the main reason continuous long-term use is discouraged. * **Withdrawal effects:** No withdrawal syndrome has been described. The expected consequence of stopping is simply a return of testosterone and libido toward the individual's untreated baseline. * **Tapering:** No tapering protocol is needed or established; because there is no evidence of dependence or rebound, use is typically stopped outright at the end of a cycle. * **Cycling for efficacy and safety:** Cycling is commonly recommended, motivated both by the theoretical possibility of diminishing response with continuous use and, more importantly, by the goal of limiting cumulative testicular, liver, and kidney exposure. * **Re-testing between cycles:** A practical convention is to allow organ-function and hormone markers to be re-checked during off periods before deciding whether to begin another cycle. ## Sourcing and Quality * **Form and standardization:** Products are typically sold as *Fadogia agrestis* stem extract, often labeled as standardized; however, because the active constituent responsible for any hormonal effect has not been identified, "standardization" claims cannot reference a validated active marker and should be viewed cautiously. * **Third-party testing:** Independent laboratory testing for identity, heavy metals, and microbial contaminants is the most important quality signal, particularly given analytical work (Avula et al., 2019) showing measurable variability in phenolic content across raw material and finished supplements. * **Botanical identity:** Buyers should look for confirmed species identity (*Fadogia agrestis* / *Vangueria agrestis*), since related plants and mislabeled material are a documented concern in the wider herbal market; a clear certificate of analysis helps confirm the correct species and part (stem). * **Product format and transparency:** Single-ingredient products with a stated extract amount are preferable to proprietary blends, which obscure the actual Fadogia dose and complicate both dosing and monitoring. * **Reputable sourcing:** Preference should go to established supplement brands that publish batch testing; because this is a niche botanical, the absence of transparent testing is a meaningful red flag rather than a minor inconvenience. ## Practical Considerations * **Time to effect:** Users typically describe noticing changes in libido or energy within a few weeks, but there are no objective data on onset; any timeline is anecdotal. * **Common pitfalls:** The most frequent mistakes are using excessive doses, taking it continuously without cycling, stacking it with several other testosterone products or alcohol, and — most consequentially — using it without baseline and follow-up bloodwork to catch hormonal or organ effects. * **Regulatory status:** In the United States, *Fadogia agrestis* is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA, the law governing supplement marketing); it is not approved by the U.S. Food and Drug Administration (FDA) as a drug and is not subject to pre-market efficacy or safety review. It is not a controlled substance, though its status on sport anti-doping lists should be checked by competitive athletes. * **Cost and accessibility:** It is inexpensive and widely available online and in supplement stores, which lowers the barrier to casual, unmonitored use — a practical risk in its own right given the thin safety data. ## Interaction with Foundational Habits * **Sleep:** Indirect and potentially bidirectional. Any genuine testosterone increase could modestly support sleep quality, while the stimulating, energizing effects some users report might, if taken late in the day, interfere with sleep onset; morning dosing is the sensible hedge. No direct sleep study exists. * **Nutrition:** Indirect. Steroid-hormone production depends on adequate dietary cholesterol and fat and on sufficient micronutrients (notably zinc and vitamin D), so an underlying nutrient-poor or very-low-fat diet may blunt any hormonal effect. Taking the extract with food may also ease gastrointestinal tolerance. * **Exercise:** Potentiating in intent. The common goal is to combine the herb with resistance training to amplify gains in strength and lean mass; mechanistically higher androgens would support training adaptations, but there is no study confirming that *Fadogia agrestis* improves exercise outcomes, and any benefit is presumed rather than demonstrated. * **Stress management:** Indirect. Chronic stress and elevated cortisol suppress the HPG axis and testosterone, so poor stress control could work against the herb's intended effect; conversely there is no evidence that *Fadogia agrestis* itself alters the stress response. ## Monitoring Protocol & Defining Success Because *Fadogia agrestis* acts on the hormonal system and carries animal signals of organ toxicity, baseline testing before starting is strongly aligned with how careful users and clinicians approach it: a pre-use panel establishes both the hormonal starting point and organ-function reference values against which change and safety can be judged. Ongoing monitoring is typically structured around the cycle: re-testing hormones and organ markers at roughly 8–12 weeks (near the end of a use block), and again during the off period, with longer-term users repeating a full panel every 6–12 months. The table below lists the core biomarkers. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|----------------| | Total testosterone | ~500–900 ng/dL (adult men) | Primary target of the intervention | Draw fasting, morning (7–10 a.m.) when levels peak; conventional labs often flag "low" only below ~264 ng/dL, lower than the functional target | | Free testosterone | ~15–25 pg/mL (adult men) | The biologically active fraction; may move more than total | Best paired with SHBG (sex hormone-binding globulin, the protein that sets the free fraction); calculated free-T is an acceptable alternative to direct assay | | Estradiol | ~20–30 pg/mL (adult men) | Detects excess conversion of testosterone to estrogen | Request a sensitive, mass-spectrometry-based assay in men; check if breast tenderness or swelling appears | | Luteinizing hormone (LH) | ~1.5–9 IU/L | Tests the proposed upstream mechanism (whether LH rises) | Interpreted alongside FSH (follicle-stimulating hormone, the partner pituitary hormone) and testosterone to locate where any effect occurs | | SHBG | ~20–45 nmol/L | Binds testosterone and sets the free fraction | SHBG is a blood protein that shifts how much testosterone is active; needed to interpret total-versus-free values | | Hematocrit (Hct) | ~40–50% | Screens for androgen-driven rise in red cells | Part of a complete blood count (CBC, a standard blood panel); values above ~52% warrant stopping | | PSA | < 1.5 ng/mL (and stable) | Prostate-safety screen in men over 40 | PSA (prostate-specific antigen) is a prostate protein used as a safety marker; a rising trend matters more than a single value | | ALT / AST | ALT ~10–26 U/L; AST ~10–26 U/L | Detects the liver injury signal seen in animals | Fasting draw; interpret against baseline; avoid alcohol before testing | | Creatinine / eGFR | Creatinine ~0.7–1.1 mg/dL; eGFR > 90 | Detects the kidney injury signal seen in animals | Hydration and recent heavy exercise or high protein intake can transiently shift values | | Lipid panel | LDL < 100 mg/dL; HDL > 45 mg/dL | Androgen shifts can affect lipids | LDL is low-density (harmful) cholesterol and HDL is high-density (protective) cholesterol; draw fasting as a general safety check on cycled hormonal agents | Qualitative markers are worth tracking alongside the labs, since they often reflect meaningful change earlier than numbers: * **Libido and sexual function:** the traditional primary outcome and the most commonly reported subjective change. * **Energy and drive:** day-to-day vitality and motivation. * **Mood and sense of well-being:** stability and outlook. * **Physical signs to watch:** breast tenderness or swelling, acne, or testicular discomfort, any of which is a prompt to stop and re-test. Success is best defined conservatively: a measurable move of testosterone toward the functional range accompanied by improved subjective libido and energy, with all organ-safety and blood-count markers holding steady — not a maximal hormone number pursued at the expense of the safety panel. ## Emerging Research * **Absence of registered trials:** As of 23 July 2026, a direct search of ClinicalTrials.gov returned no registered interventional trials of *Fadogia agrestis* for testosterone or any other indication; consequently there are no NCT identifiers to list. This registry gap is itself the most important "emerging research" fact — the field has not advanced to human study. * **The case for a first human trial (could strengthen the case):** The single most consequential next step would be a controlled human study measuring whether the herb raises testosterone and luteinizing hormone as it does in rodents. The rationale rests on the reproducible animal signal in [Yakubu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16281088/); a positive, safely conducted human result would move the intervention out of the speculative category. * **Human pharmacokinetic and constituent identification (could strengthen or weaken the case):** Identifying the active compound and characterizing its human absorption, half-life, and metabolism is a prerequisite for rational dosing. Analytical groundwork such as [Avula et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30170324/) provides marker compounds that future pharmacokinetic work could track; results could either validate a plausible mechanism or reveal that the marketed extracts lack meaningful active content. * **Dose-toxicity and reproductive-safety studies (could weaken the case):** The organ- and testicular-toxicity findings — [Yakubu et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18023305/) on testicular function and [Yakubu et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19755438/) on liver and kidney toxicity — need to be extended into defined no-effect and harm thresholds, ideally in a second species and eventually in humans. Findings here could sharply constrain safe use, particularly for men concerned with fertility. * **Erectile-function mechanism work (could strengthen the case):** The paroxetine-model finding in [Ogunro & Yakubu, 2023](https://pubmed.ncbi.nlm.nih.gov/35969364/) points to a possible pro-erectile action beyond raw testosterone; replication and mechanistic follow-up could define a distinct, testable indication for the herb. ## Conclusion *Fadogia agrestis* is a West African shrub sold as a supplement on the promise that it can raise a man's testosterone and sharpen sexual drive. The case for it rests almost entirely on a small number of animal experiments, in which rodents given the stem extract showed marked rises in testosterone and more active sexual behavior. Those findings are striking, but they have never been reproduced in people, and results in rodents often fail to carry over to humans. The proposed benefits for muscle, mood, and energy remain guesswork built on top of the hormone claim. The safety picture deserves equal weight. The same animal work that suggests a benefit also points to possible harm to the testes, liver, and kidneys when the amount or duration is pushed, and there is no human safety record to lean on. In practice, people who use it tend to keep doses modest, take breaks rather than using it continuously, and track their bloodwork closely. Overall, the evidence is thin and weighted toward early animal work, with genuine unknowns on both the benefit and the risk side. *Fadogia agrestis* is best understood today as an experimental option whose promise is real but unproven, and whose safety over time is still an open question. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**